What is the recommended management of PR3‑positive ANCA‑associated renal‑limited vasculitis?

Management of PR3-Positive ANCA Renal-Limited Vasculitis

For PR3-positive ANCA renal-limited vasculitis, initiate induction therapy with glucocorticoids combined with either rituximab or cyclophosphamide, followed by maintenance therapy for 18 months to 4 years to prevent relapse. 1

Induction Therapy (First 3-6 Months)

Choice of Immunosuppressive Agent

The selection between rituximab and cyclophosphamide depends critically on renal function severity:

• For severe renal impairment (serum creatinine >4 mg/dl or >354 μmol/l): Cyclophosphamide is preferred over rituximab, as there are limited data supporting rituximab in this setting. Alternatively, consider combining rituximab with 2 intravenous pulses of cyclophosphamide 1

• For moderate renal impairment (creatinine <4 mg/dl): Either rituximab or cyclophosphamide is appropriate 1

• PR3-positive patients specifically: Note that PR3-ANCA positivity is a known risk factor for relapse, which may favor rituximab for its superior relapse prevention 1

Immunosuppressive Dosing

Cyclophosphamide options: 1

• Oral: 2 mg/kg/day for 3 months (maximum 6 months if ongoing activity)

  • Reduce to 1.5 mg/kg/day if age >60 years
  • Reduce to 1.0 mg/kg/day if age >70 years
  • Reduce by 0.5 mg/kg/day if GFR <30 ml/min/1.73 m²

• Intravenous: 15 mg/kg at weeks 0,2,4,7,10,13 (extend to weeks 16,19,21,24 if needed)

  • Reduce to 12.5 mg/kg if age >60 years
  • Reduce to 10 mg/kg if age >70 years
  • Reduce by 2.5 mg/kg if GFR <30 ml/min/1.73 m²

Rituximab: 375 mg/m²/week × 4 weeks 1

Combined approach for severe disease: Rituximab 375 mg/m²/week × 4 weeks PLUS intravenous cyclophosphamide 15 mg/kg at weeks 0 and 2 1

Glucocorticoid Regimen

Use the reduced-dose PEXIVAS protocol (weight-based dosing): 1

• Week 1: 50-75 mg prednisolone daily (based on weight)
• Weeks 2-4: Rapid taper to 20-30 mg daily
• Weeks 5-20: Gradual reduction to 5 mg daily
• After week 20: Maintain 5 mg daily through first year

Alternative: Avacopan 30 mg twice daily can replace glucocorticoids entirely, particularly beneficial for patients at high risk of steroid toxicity or those with lower GFR who may achieve better GFR recovery 1

Plasma Exchange Consideration

Consider plasma exchange for: 1

• Serum creatinine >3.4 mg/dl (>300 μmol/l)
• Patients requiring dialysis or with rapidly increasing creatinine
• Diffuse alveolar hemorrhage with hypoxemia

Important caveat: One retrospective study specifically showed plasma exchange benefit in PR3-positive patients with eGFR <60 ml/min/1.73 m², demonstrating reduced mortality, end-stage renal disease, and relapses at one year 2. This suggests PR3-positive renal vasculitis may particularly benefit from plasma exchange even with moderate renal impairment.

Maintenance Therapy (After Remission Induction)

Duration: 18 months to 4 years after achieving remission 1

Agent Selection

First-line options: 1

• Rituximab (preferred for PR3-positive patients due to higher relapse risk):

  • MAINRITSAN protocol: 500 mg × 2 at remission, then 500 mg at months 6,12, and 18
  • OR RITAZAREM protocol: 1000 mg after induction, then at months 4,8,12, and 16

• Azathioprine: 1.5-2 mg/kg/day at complete remission

  • Decrease by 25 mg every 3 months after 1 year
  • For extended therapy (up to 4 years): maintain 1.5-2 mg/kg/day for 18-24 months, then reduce to 1 mg/kg/day until 4 years, then taper by 25 mg every 3 months

Alternative agents if azathioprine intolerant: 1

• Mycophenolate mofetil: 2000 mg/day (divided doses) for 2 years
• Methotrexate: Only if GFR ≥60 ml/min/1.73 m²

Concurrent Glucocorticoids

Continue prednisolone 5-7.5 mg/day for 2 years, then slowly reduce by 1 mg every 2 months 1

Critical Management Points

PR3-Specific Considerations

PR3-positive patients have inherently higher relapse risk compared to MPO-positive patients 1. This makes:

• Longer maintenance therapy duration (closer to 4 years) more appropriate
• Rituximab potentially preferable over azathioprine for maintenance
• Close ANCA monitoring essential, as persistence or rising PR3-ANCA levels predict relapse 1

Treatment Setting

Patients should be managed at centers with AAV experience 1

Common Pitfalls

• Underestimating relapse risk: PR3-positivity itself is a major relapse predictor; don't prematurely discontinue maintenance therapy
• Inadequate steroid tapering: Follow structured protocols rather than arbitrary tapering
• Missing the plasma exchange window: In PR3-positive disease with moderate-to-severe renal impairment, early plasma exchange may improve outcomes 2
• Ignoring ANCA trends: Rising or persistent PR3-ANCA should prompt treatment intensification before clinical relapse